AMAP102 is given orally and works by inhibiting the production of two important cytokines linked to rheumatoid arthritis: interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-?). High levels of IL-6 and its receptor have been observed in the serum of patients with rheumatoid arthritis and correlate with high rheumatic activity.

"When the clinical phase is over we will look for partners for the next stage in the development of AMAP102, which also applies to other substances that are in the preclinical phase," comments CEO Owe Gårlin.

AnaMar is based in Göteborg and has a research branch in Lund. The company focuses on the identification and treatment of chronic joint diseases, particularly rheumatism. AnaMar has a portfolio consisting of five drug projects and three biomarkers originating from academic institutions and selected partners.